PQUS0.550%
as of Jul 21
CME
GrowthCME GROUP INC A
CME Group Inc., together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, and foreign exchange; and agricultural, energy, and metals commodities, as well as fixed income and foreign currency trading services. The company provides clearing house services, including clearing, settling, and guaranteeing futures and options contracts, and cleared swaps products traded through its exchanges.
Close · 3M
-23.18%
Held by 2 AI ETFs
AIVL0.176%
as of Jul 17
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals12
Win rate25% (3/12)
Avg buy return-8.54%
PQUS · Weight increase · 2d
The weight change in CME for PQUS displays a clear step-up, moving from a stable 0.42% in early July to 0.54% by July 10, following a brief dip. This upward adjustment in allocation for the US large-cap financials stock occurs as CME trades near the lower end of its 52-week range, having experienced a 26.6% decline over the last 90 days. Pictet Asset Management's AI ranking system likely identified CME's 24.55% revenue growth and 15.35% ROE as increasingly compelling fundamentals given the asset's reduced price point. The fund's strategy, involving periodic rebalancing within a US large-cap universe and sector-balance rules, facilitates such measured accumulations in a stock demonstrating strong financial health amidst market depreciation.
weight 0.410% → 0.540% (+0.130 pp)·stock down 6.1% in the 30 days before
Jul 10·entry $240.27·now $245.11Drifting
+2.01%
since Jul 10
PQUS · Weight decrease · 2d
PQUS, managed by Pictet Asset Management, applies an AI ranking system to its approximately 165 US large-cap holdings, adhering to periodic rebalancing rather than daily adjustments. The observed consecutive weight decreases for CME from 0.43% to 0.39% over late June and early July strongly suggest the fund's AI initiated a reduction during one such rebalance cycle. This action likely stemmed from CME's recent market performance, with a 30-day return of -23.6% and the stock now trading at 71% of its 52-week high. Even with a revenue growth of 24.55%, the AI's re-evaluation, possibly influenced by its inherent sector-balance and concentration rules, seems to have prioritized reducing exposure to CME at its current $231.00 price point. The persistent trimming reflects the AI's systematic approach to portfolio construction, prioritizing its ranking and risk management parameters.
weight 0.410% → 0.390% (-0.020 pp)·stock down 5.6% in the 30 days before
Jul 2·entry $236.60·now $245.11
+3.60%
since Jul 2
PQUS · Weight decrease · 2d
CME GROUP INC A currently trades at $221.00, marking its 52-week low and a significant drop to 68% of its high, following 30-day and 90-day returns of -25.8% and -27.0% respectively. This sustained price depreciation likely triggered a re-evaluation by Pictet Asset Management's AI ranking system for PQUS, despite CME's underlying financials showing 24.55% revenue growth and a 15.35% return on equity. During a periodic rebalance, the AI's algorithm, which applies sector-balance and concentration rules, responded to CME's poor market performance, leading to a consecutive weight decrease from 0.43% to 0.41% between June 26th and June 28th. This move suggests the AI system adjusted the stock's position within its ~165 US large-cap portfolio as its relative attractiveness waned, reflecting a systematic response to the pronounced negative price action rather than the company's operational figures alone.
weight 0.430% → 0.410% (-0.020 pp)·stock down 20.8% in the 30 days before
Jun 28·entry $218.58·now $245.11
+12.14%
since Jun 28
PQUS · Weight increase · 2d
The weight in CME Group in PQUS shows an intermittent upward adjustment, culminating in a notable increase from 0.26% to 0.32% on June 12th, rather than a continuous daily change. This stepped elevation aligns with Pictet Asset Management's stated periodic rebalancing schedule for PQUS, indicating the AI ranking system likely identified CME as a compelling addition within the US large-cap universe. Trading at $262.18, near its 52-week low after declines across 30, 90, and 1-year periods, the stock presented an opportune entry point. Despite the recent price action, CME's underlying strength is indicated by its 24.55% revenue growth and 15.35% return on equity, suggesting the AI recognized value during a period of market pessimism for the stock, while also adhering to its sector-balance and concentration rules for the financials sector.
weight 0.260% → 0.320% (+0.060 pp)·stock down 9.3% in the 30 days before
Jun 12·entry $269.53·now $245.11Fresh
-9.06%
since Jun 12
AIVL · Weight increase · 2d
WisdomTree's AIVL ETF, which leverages AI to score names within a pre-filtered US value-factor pool using fundamental and valuation metrics, made a series of upward adjustments to its CME position in early July. Given the fund’s objective to distinguish genuine value from value traps, CME’s significant price downturn likely drew the AI's attention. With the stock experiencing a 26.6% decline over 90 days, the AI module likely re-evaluated CME's attractiveness against its underlying financial health. The company's 24.55% revenue growth and 15.35% ROE would provide indicators of business strength, suggesting it was not a value trap, thus informing the consecutive weight increases observed.
weight 0.169% → 0.177% (+0.009 pp)·stock down 5.6% in the 30 days before
Jul 8·entry $243.07·now $245.11Fresh
+0.84%
since Jul 8
AIVL · Weight increase · 2d
CME is currently trading at $236.60, sitting at 72% of its 52-week high after seeing its value decrease by 18.4% over 30 days and 25.8% over 90 days. This significant price depreciation likely brought CME to a level where AIVL’s AI model began to score it more favorably within its US value-factor pool. While its PER is 19.92 and PBR is 3.43, the AI likely weighed these valuation metrics against CME's underlying financials, which include a 24.55% revenue growth and 15.35% return on equity. The consecutive weight increase from 0.1621% to 0.1727% between June 30th and July 2nd suggests the WisdomTree AI concluded the stock’s recent decline presented a genuine value opportunity rather than indicating a value trap, prompting its rebalancing action.
weight 0.162% → 0.173% (+0.011 pp)·stock down 5.6% in the 30 days before
Jul 2·entry $236.60·now $245.11Drifting
+3.60%
since Jul 2
AIVL · Weight decrease · 3d
CME Group shares currently trade at $218.58, at the very bottom of their 52-week range ($218.58 to $326.46), reflecting significant declines of 26.9% over 30 days and 28.1% over 90 days. Despite this substantial price decline, AIVL has consistently decreased its weighting of CME from 0.2019% to 0.1626% over several days in late June. AIVL’s AI, which scores names based on fundamentals like margins and return on capital, plus valuation metrics such as P/E and P/B to distinguish genuine value from value traps, appears to be re-evaluating CME. While CME demonstrates 24.55% revenue growth and a 15.35% return on equity, its P/E of 20.31 and P/B of 3.43, even at this reduced price level, may be signaling to the AI that the stock's valuation or underlying quality metrics are less appealing within its US value-factor universe. This sustained weight reduction suggests the AI algorithm is not finding a compelling value proposition in CME, considering its price action and financial profile against the ETF’s specific criteria.
weight 0.181% → 0.163% (-0.019 pp)·stock down 20.8% in the 30 days before
Jun 26·entry $221.00·now $245.11
+10.91%
since Jun 26
AIVL · Weight decrease · 2d
CME Group shares have fallen substantially, reaching a 52-week low of $221.00 and a 30-day return of -25.8%, positioning the stock at 68% of its 52-week high. While such a price decline often draws attention from value-oriented strategies, AIVL’s AI-driven methodology actively screens for genuine value versus potential value traps within its US value-factor universe. The fund's AI likely analyzed CME’s current PER of 20.31 and PBR of 3.43 against its 15.35% ROE and 24.55% revenue growth, determining that even at a lower price, the valuation or underlying fundamental picture did not meet its criteria for long-term value. This assessment appears to be the driving force behind the consecutive reduction in CME’s weight within AIVL's portfolio, decreasing from 0.2019% on June 12th to 0.1652% by June 25th.
weight 0.182% → 0.165% (-0.016 pp)·stock down 20.4% in the 30 days before
Jun 25·entry $225.00·now $245.11
+8.94%
since Jun 25
AIVL · Weight decrease · 3d
AIVL exhibits a pattern of consecutive weight reduction in CME, observed through declines from 0.2019% on June 12th down to 0.1817% by June 22nd, indicating a systematic re-evaluation. This steady divestment occurs even as CME’s price has fallen significantly, now sitting at its 52-week low after a 12.8% drop in 30 days, a scenario that might typically attract traditional value investors. However, AIVL's AI, tasked with distinguishing genuine value from value traps within its US value-factor pool, likely scrutinizes CME’s valuation metrics—such as its PER of 20.87 and PBR of 3.43—in conjunction with underlying fundamentals. The AI appears to be concluding that despite CME's 24.55% revenue growth and 15.35% ROE, and its recent price depreciation, the stock does not present compelling genuine value aligned with the fund's criteria, leading to a measured reduction in exposure over time.
weight 0.202% → 0.182% (-0.020 pp)·stock down 15.5% in the 30 days before
Jun 22·entry $245.20·now $245.11
-0.04%
since Jun 22
AIVL · Weight decrease · 2d
WisdomTree's AIVL, which leverages AI to distinguish genuine value from potential value traps within its approximately 100 US value stocks, initiated a consecutive weight decrease in CME GROUP INC A. The AI's models likely re-evaluated CME's standing, perceiving that its PER of 20.87, even after significant price drops, did not align with the fund's strict criteria for genuine value within its pre-filtered universe. This adjustment occurred as CME's price fell to $246.38, registering a 19.7% decrease over the last 90 days. The fund's periodic rebalancing mechanism determined that CME's profile, including its fundamentals and valuation metrics, warranted a reduced allocation.
weight 0.202% → 0.184% (-0.018 pp)·stock down 18.5% in the 30 days before
Jun 18·entry $246.38·now $245.11
-0.52%
since Jun 18
AIVL · Weight increase · 2d
weight 0.193% → 0.199% (+0.006 pp)·stock down 10.7% in the 30 days before
Jun 5·entry $257.40·now $245.11Fresh
-4.77%
since Jun 5
AIVL · Weight decrease · 2d
weight 0.235% → 0.193% (-0.043 pp)·stock down 13.0% in the 30 days before
Jun 3·entry $252.64·now $245.11
-2.98%
since Jun 3
AIVL · Weight increase · 2d
The AI ETF likely increased its weight in CME due to its robust 24.55% revenue growth and strong 15.35% ROE, indicating the algorithm prioritizes fundamental strength and profitability within the financial sector despite its higher valuation. Retail investors should recognize that AI-driven funds often look beyond traditional valuation multiples, emphasizing consistent growth and operational efficiency when selecting companies for increased allocation.
weight 0.219% → 0.231% (+0.012 pp)·stock up 0.0% in the 30 days before
May 13·entry $297.13·now $245.11Fresh
-17.51%
since May 13
AIVL · Accumulation · 4d
The AI ETF is likely accumulating CME due to its exceptional revenue growth of 24.55% and strong 15.35% ROE, indicating robust financial health and a promising long-term growth trajectory in the financial sector. The gradual accumulation strategy allows the AI to build a position opportunistically without significant market disruption. Retail investors can adopt a similar patient approach, focusing on companies with strong, sustainable growth fundamentals and using dollar-cost averaging to mitigate risk rather than trying to perfectly time market entry.
weight 0.225% → 0.229% (+0.004 pp)·stock down 4.9% in the 30 days before
May 4·entry $290.29·now $245.11Fresh
-15.56%
since May 4
AIVL · Accumulation · 3d
The AI ETF is likely gradually accumulating CME due to its robust 24.55% revenue growth and strong 15.35% ROE, signaling a healthy and profitable business that justifies its current valuation multiples. Retail investors can learn from this by prioritizing companies with strong fundamental performance and considering a disciplined, phased buying approach to build positions in quality growth stocks.
weight 0.225% → 0.227% (+0.002 pp)·stock down 2.5% in the 30 days before
May 1·entry $289.54·now $245.11Fresh
-15.35%
since May 1
AIVL · Weight increase · 2d
stock down 3.5% in the 30 days before
Apr 29·entry $287.27·now $245.11Fresh
-14.68%
since Apr 29
AIEQ · Exit · 1d
Despite CME's recent revenue growth of 24.55% and a return on equity of 15.35%, figures that would typically be viewed favorably for a fundamentals-driven approach, its price-to-earnings ratio of 19.92 and price-to-book ratio of 3.43 were evaluated within AIEQ's broad market, fundamentals, and sentiment hybrid framework. The substantial -23.6% 30-day return and -26.4% 90-day return, placing CME at 71% of its 52-week high, strongly suggest that IBM Watson NLP's ingestion of news, filings, and social posts indicated deteriorating sentiment. This pronounced negative sentiment, particularly as the stock approached its 52-week low of $218.58, prompted EquBot's risk overlay to entirely remove CME from the AIEQ portfolio on July 1st, 2026. Given AIEQ's daily rebalancing and high-turnover characteristics, the observed persistent downtrend in price action and associated sentiment deterioration likely triggered the rapid exit from the position.
weight 0.260% → 0 (exited)·stock down 10.4% in the 30 days before
Jul 1·entry $231.00·now $245.11
+6.11%
since Jul 1
AIEQ · Weight decrease · 2d
Amplify ETFs' AIEQ, leveraging its IBM Watson NLP engine to ingest daily news, filings, and social posts, appears to have identified a decline in positive sentiment or fundamental indicators for CME Group. This sophisticated daily analysis, fundamental to managing its portfolio of 140-180 US stocks, translated into a consecutive weight reduction for CME from 0.32% to 0.30% between June 15th and June 17th. The fund's rapid rebalancing capability allows it to respond to such shifts, particularly as CME has experienced a -12.4% return over the past 30 days. This adjustment reflects the AI’s real-time assessment of the stock’s deteriorating outlook at its current price level.
weight 0.320% → 0.300% (-0.020 pp)·stock down 17.2% in the 30 days before
Jun 17·entry $252.54·now $245.11
-2.94%
since Jun 17
AIEQ · Weight increase · 2d
CME shares are presently trading at $262.18, representing 80% of their 52-week high and reflecting negative returns across the 30-day, 90-day, and one-year periods. This price depreciation, placing the stock near the lower bound of its annual range, likely prompted IBM Watson NLP to scrutinize CME's position for emerging positive sentiment. The AI system, tasked with ingesting vast amounts of data including news and filings, probably detected favorable shifts in underlying business prospects, especially considering the company’s 24.55% revenue growth and 15.35% ROE. Consequently, EquBot's daily ranking and risk overlay initiated a series of weight increases for CME within AIEQ, taking the allocation from 0.29% to 0.32% between June 9 and June 11, aligning with the fund's daily rebalancing and high-turnover approach to capitalize on perceived value.
weight 0.290% → 0.320% (+0.030 pp)·stock down 8.2% in the 30 days before
Jun 11·entry $262.18·now $245.11Fresh
-6.51%
since Jun 11
AIEQ · New entry · 1d
weight 0 → 0.310% (new)·stock down 4.8% in the 30 days before
May 30·entry $257.76·now $245.11Fresh
-4.91%
since May 30
QRFT · Exit · 1d
Currently priced at $250.53, CME Group Inc. sits at 77% of its 52-week high, following a -11.9% return over the last 30 days and a -9.8% decline over the past year. This prolonged negative price trajectory likely triggered the Qraft AI’s momentum factor, a key component of QRFT’s strategy that also considers value, quality, and low-volatility. Despite CME’s revenue growth of 24.55% and a 15.35% ROE, its PER of 21.51 and PBR of 3.43, when juxtaposed with the stock’s depreciation, might not have signaled sufficient value or quality to offset the adverse momentum. The AI's weekly rebalancing mechanism, after observing a sustained downtrend and likely finding stronger opportunities elsewhere via its proprietary alternative-data overlays, thus completed the divestment of CME from the portfolio to 0.00% on June 2, 2026.
weight 0.190% → 0 (exited)·stock down 13.5% in the 30 days before
Jun 2·entry $250.53·now $245.11
-2.16%
since Jun 2
-14.79%
since Apr 17
QRFT · Weight increase · 2d
stock down 2.6% in the 30 days before
Apr 6·entry $308.57·now $245.11Fresh
-20.57%
since Apr 6
-16.61%
since Mar 25
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of Jun 28
The AI ETFs are showing a consistent trend of decreasing weight in CME Group, signaling a reduction in exposure. This observed activity aligns with the framework's 'Fail' verdict, particularly given the absence of a clear margin of safety at the current price.
- Circle of CompetenceThe predictable, transaction-based unit economics of a leading financial exchange allow for reasonable projection of ten-year cash flows.
- Economic MoatCME benefits from strong network effects, high switching costs for participants, and significant regulatory barriers to entry, which create an enduring economic moat.
- ManagementThe provided data does not offer sufficient information to assess management's candor, capital allocation discipline, or direct alignment with shareholder interests.
- Financial HealthInsufficient financial history and specific metrics are provided to fully evaluate the 10-year average ROE, debt manageability, or owner earnings consistency required by the framework.
- Margin of SafetyThe provided valuation multiples do not clearly indicate a defensible discount to a conservative estimate of intrinsic value, making a margin of safety difficult to ascertain without further analysis.
CME Group operates within a predictable circle of competence and possesses strong economic moats through network effects, high switching costs, and regulatory barriers. However, the limited financial data prevents a full assessment of its financial health and management quality. Crucially, the current valuation multiples do not indicate a defensible margin of safety, leading to a 'Fail' verdict within this investment framework.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.